Taiwan innovative biotech instrument company Syncell Inc. today announced the successful completion of a NT$750 million Series A funding round, led by Taiwania Capital. The round also saw participation from heavyweight investors including Everbright Biofund, National Development Fund, Abico Group, Himalaya Venture Fund, Ta Ya Venture Capital, BE Health, Isaiah Capital, Hua Nan Venture Capital, First Venture Capital, Dongan Investment, ITIC, and Taiwan Cooperative Venture Capital. The capital raised will be used to accelerate international market expansion and technology development, positioning Syncell as a leading Taiwanese biotech company creating internationally recognized high-end instruments.

Syncell’s core product, the patented “Optical Targeting System,” precisely locates unknown disease-related proteins in patient samples, significantly enhancing early disease biomarker discovery and speeding up new drug development. This technology has attracted strong interest from international pharmaceutical companies, medical centers, and academic institutions, including adoption by the Mayo Clinic, the largest hospital in the United States. Currently, Syncell’s customers span the U.S., Europe, and Asia, with a global sales team actively deployed.

Founder and CEO Dr. Jung-Chi Liao stated, “We sincerely appreciate the strong confidence shown by our Series A investors, which further fuels our determination to bring Taiwanese technology to the global stage. Over the past five years, we have steadily translated research outcomes from my lab at Academia Sinica into industrial applications. We are honored that our products are embraced by world-class institutions. Our team combines cross-disciplinary talents in AI, biotechnology, mechatronics, mass spectrometry, software and firmware, and sales, enabling us to efficiently achieve key milestones from R&D to commercialization.”

Established only five years ago, Syncell has attracted senior executives from global industry leaders over the past year. In the last 12 months, the company has generated over NT$100 million in revenue, demonstrating both technological and market validation. Going forward, Syncell will continue expanding its presence in North American and European markets while accelerating product mass production and application development.

Dr. Jerome Shen, Partner of the lead investor Taiwania Capital’s biotech fund, remarked, “We observed that Syncell’s management team exhibits exceptional execution capability and strategic vision. Their innovation is matched by robust commercial execution, making them a rare startup able to integrate Taiwanese mechatronics expertise with the international biotech market.”

Everbright Biofund Chairman Wei-Jao Chen also commented, “Syncell’s Optical Targeting technology is pioneering worldwide, enabling high-throughput, high-resolution identification of disease-associated proteins. It provides tremendous value for understanding disease mechanisms and drug development, and we see it as a highly promising technology with great international potential.”

Syncell plans to further strengthen international collaborations and market penetration, aiming to become a key global supplier of biotech instruments for disease detection and new drug development, setting a new benchmark for Taiwan’s biotech industry.

Resource: 新析生技7.5億完募 打造台灣國際級生技高階儀器國際品牌